1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD, 2017, http://www.goldCOPD.org.
[2]
2. Vestbo J, Hurd SS, Agustí AG,et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.Am J Respir Crit Care Med, 2013, 187(4): 347-365.
[3]
3. Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol, 2011, 52(1): 21-27.
[4]
4. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med, 2012, 12:26.
[5]
5. Graat-Verboom L, Wouters EF, Smeenk FW, et al.Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J, 2009, 34(1): 209-218.
[6]
6. Papaioannou A, Watts NB, Kendler DL,et al. Diagnosis and management of vertebral fractures in elderly adults. Am J Med, 2002, 113(3): 220-228.
[7]
7. Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res, 1992, 7(2): 221-227.
[8]
8. Majumdar SR, Villa-Roel C, Lyons KJ, et al.Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir Med, 2010, 104(2): 260-6.
[9]
9. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med, 1996, 101(3): 262-269.
[10]
10. Watanabe R, Tanaka T, Aita K, et al. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab, 2015, 33(4): 392-400.
[11]
11. Regan EA, Jaramillo J. It’s the fracture that matters -bone disease in COPD patients. COPD, 2012, 9(4): 319-321.
[12]
12. Lehouck A, Boonen S, Decramer M, et al. COPD, bone metabolism, and osteoporosis. Chest, 2011, 139(3): 648-657.
[13]
13. Graat-Verboom L, van den Borne BE, Smeenk FW, et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res, 2011, 26(3): 561-568.
15. Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford), 2009, 48(suppl 4): iv3-8.
[16]
16. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol, 2008, 19(5): 444-451.
[17]
17. Steiner NK, Milhorn D, Hammett-Stabler C. Osteoporosis in men. Clin Biochem, 2014, 47(10-11): 950-959.
[18]
18. Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res, 2011, 12:157.
[19]
19. Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort study. Eur Respir J, 2010, 35(3): 540-548.
[20]
20. Bolton CE, Stone MD, Edwards PH, et al. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis, 2009, 6(2): 81-87.
[21]
21. Zhang PF, Pan L, Luo ZY, et al. Interrelationship of circulating matrix metalloproteinase-9, TNF-α and OPG/RANK/RANKL systems in COPD patients with osteoporosis. COPD, 2013, 10(6): 650-6.
[22]
22. Pauwels RA, Buist AS, Ma P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care, 2001, 46(8): 798-825.
[23]
23. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int, 2001, 68(5): 259-270.
[24]
24. Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int, 2012, 23:2081-2092.
28. F？rli L, Halse J, Haug E, et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med, 2004, 256:56-62.
[29]
29. Romme EA, Rutten EP, Smeenk FW, et al. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann Med, 2013, 45:91-96.
[30]
30. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev, 2001, 22(4): 477-501.
[31]
31. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 2004, 19(6): 893-9.
[32]
32. Suda T, Takahashi N, Udagawa N, et al. MartinTJModulation of osteoclast differentiation and function by the newmembers of the tumor necrosis factor receptor and ligand families. Endocr Rev, 1999, 20:345-357.
[33]
33. Dimai HP, Domej W, Leb G,et al. Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J Bone Miner Res. 2001 Nov;16(11):2132-41.
[34]
34. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med, 2013, 45(3): 291-300.
[35]
35. Garcia-Rio F, Miravitlles M, Soriano JB, et al.EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease:a population-based study. Respir Res, 2010, 11:63.
[36]
36. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, 59(7): 574-580.
[37]
37. Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine, 2012, 42(1): 190-195.
